Shield Therapeutics plc (AIM: STX)

Shield Therapeutics Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Nov 21, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	23	52	18	96	75	210
Market Cap Growth	-69.94%	186.53%	-80.96%	28.62%	-64.39%	490.73%
Enterprise Value	32	46	16	73	68	203
Last Close Price	0.03	0.07	0.07	0.43	0.60	1.69
PS Ratio	1.32	5.10	4.01	85.63	9.82	386.40
PB Ratio	53.95	4.44	3.37	3.20	3.37	8.64
P/TBV Ratio	-	4.82	4.15	5.57	8.91	24.79
EV/Sales Ratio	1.91	4.50	3.48	65.49	8.96	374.41
EV/EBITDA Ratio	-	-	-	-	3878.24	-
EV/FCF Ratio	-1.96	-	-	-	-	-
Debt / Equity Ratio	36.91	1.35	1.04	0.00	0.00	0.00
Debt / EBITDA Ratio	-	-	-	-	1.17	-
Asset Turnover	0.49	0.35	0.14	0.04	0.30	0.02
Inventory Turnover	4.06	3.65	1.63	0.65	1.16	0.92
Quick Ratio	0.90	1.83	0.62	3.73	1.60	1.27
Current Ratio	1.05	2.28	0.95	4.64	2.32	1.53
Return on Equity (ROE)	-261.66%	-308.60%	-179.19%	-55.46%	-8.43%	-24.25%
Return on Assets (ROA)	-47.85%	-51.93%	-49.37%	-32.97%	-3.91%	-14.14%
Return on Capital (ROIC)	-79.25%	-80.56%	-63.24%	-35.65%	-4.31%	-15.53%
Earnings Yield	-197.80%	-49.88%	-225.97%	-15.13%	-2.58%	-3.17%
FCF Yield	-114.25%	-55.98%	-102.82%	-14.33%	-1.37%	-1.46%
Buyback Yield / Dilution	-59.90%	-209.85%	-14.08%	-74.36%	-0.21%	-0.48%
Total Shareholder Return	-59.90%	-209.85%	-14.08%	-74.36%	-0.21%	-0.48%

Source: S&P Capital IQ. Standard template. Financial Sources.